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Abstract
Background: DNA and RNA fractions from whole blood, serum and plasma are increasingly popular analytes
that are currently under investigation for their utility in the diagnosis and staging of disease. Small non-coding
ribonucleic acids (sRNAs), specifically microRNAs (miRNAs) and their variant isoforms (isomiRs), and transfer RNA
(tRNA)-derived small RNAs (tDRs) comprise a repertoire of molecules particularly promising in this regard.
Results: In this designed study, we compared the performance of various methods and kits for isolating
circulating extracellular sRNAs (ex-sRNAs). ex-sRNAs from one healthy individual were isolated using five
different isolation kits: Qiagen Circulating Nucleic Acid Kit, ThermoFisher Scientific Ambion TRIzol LS Reagent,
Qiagen miRNEasy, QiaSymphony RNA extraction kit and the Exiqon MiRCURY RNA Isolation Kit. Each isolation
method was repeated four times. A total of 20 small RNA sequencing (sRNAseq) libraries were constructed,
sequenced and compared using a rigorous bioinformatics approach. The Circulating Nucleic Acid Kit had the
greatest miRNA isolation variability, but had the lowest isolation variability for other RNA classes (isomiRs, tDRs,
and other miscellaneous sRNAs (osRNA). However, the Circulating Nucleic Acid Kit consistently generated the
fewest number of reads mapped to the genome, as compared to the best-performing method, Ambion TRIzol,
which mapped 10% of the miRNAs, 7.2% of the tDRs and 23.1% of the osRNAs. The other methods performed
intermediary, with QiaSymphony mapping 14% of the osRNAs, and miRNEasy mapping 4.6% of the tDRs and
2.9% of the miRNAs, achieving the second best kit performance rating overall.
Conclusions: In summary, each isolation kit displayed different performance characteristics that could be
construed as biased or advantageous, depending upon the downstream application and number of samples
that require processing.
Background
Biomarkers come in many forms—proteins, nucleic
acids, metabolites, small molecules—and can be evalu-
ated as indicators of specific metabolic, physiologic, or
pathologic states or conditions. Biomarkers have been
used in numerous clinical assays to detect the presence
or risk of developing disease. Biomarker assays should
be conducted from an easily accessible source with min-
imally invasive medical procedures. One class of mole-
cules, e.g., small RNAs (sRNAs), with great potential for
biomarker utility is micro RNAs (miRNAs). miRNAs are
20-25nts in length and are one class of sRNAs that play
vital roles in multiple cellular and developmental pro-
cesses, primarily via post-transcriptional regulation of
gene expression [1]. Currently, over 1880 annotated
miRNAs (miRBase v21) have been reported in the hu-
man transcriptome, targeting >60% of coding genes in
the genome [2]. These miRNAs are primarily transcribed
by RNA polymerase II either as standalone transcription
units or as part of the non-coding intronic sequence
within a host gene. They typically function through in-
teractions with Argonaute family proteins, which lead to
the formation of a RNA-induced silencing complex
(RISC) and suppressed gene expression [3]. At certain
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stages of the cell cycle, miRNAs have also been reported
to assume an activating role in gene expression [4].
Mature miRNAs are also released from cells into circu-
lation, and are therefore detectable in serum [5, 6],
plasma [7] and all biological fluids tested. As such,
extracellular RNA, particularly ex-sRNAs, have great
potential as disease biomarkers in non-invasive assays.
miRNAs are becoming increasingly recognized for
their potential to diagnose and stage disease, with cancer
being a great example [8–13]. The utility of these miR-
NAs, in part, is due to their relatively high copy number,
stable biochemical properties under clinical conditions,
and discriminating transcription that can characterize
unique physiological abnormalities. Despite the wide-
range of studies that have been conducted to find sRNAs
and disease associations, technical challenges continue
to deter the utilization of sRNAs in clinical applications.
One of the biggest issues for sRNA-based studies is the
relatively low concentration of sRNAs present in serum
and plasma samples. Currently, there are several miRNA
extraction kits that are able to work with low input
amounts and extract sRNAs from blood products. Previ-
ous sRNA studies [14–16] used a variety of extraction
approaches, each with their own advantages and disad-
vantages. Yet, no consensus exists on the best approach.
Methods for RNA characterization can be classified
into two major categories: hybridization-based micro-
array or synthesis/base-extension-based. Earlier sRNA
studies mostly consisted of real-time quantitative poly-
merase chain reaction (RT-PCR) or hybridization-based
assays. However, with the advancement of high-
throughput sequencing technology, high-throughput
sRNA screening has shifted from hybridization-based
microarray technology to sRNAseq technology. One of
the most considerable advantages that sRNAseq offers
over microarrays is that it does not limit the detection of
sRNA to a set of previously known targets. sRNAseq be-
gins by constructing a cDNA sequence library reversely
transcribed from short sRNA selected via different
methods, e.g., size-selected gel electrophoresis. The
prepared, indexed and pooled cDNA library can then be
sequenced on different massive parallel sequencing
platforms. Subsequent bioinformatic analysis of sRNA-
seq data provides the identification, quantification and
differential expression of sRNAs. Since size-selection is
agnostic to sRNA class (excluding potential chemical
modifications), it has the potential to capture many spe-
cies of sRNAs short in length, including miRNAs,
miRNA isoforms (isomiRs) [17, 18], transfer RNA
(tRNA)-derived small RNAs (tDRs) [19, 20], and other
miscellaneous sRNAs (osRNAs) [21, 22]. IsomiRs are the
isoforms of miRNA. The isomiRs usually have alterna-
tive seed sequences as compared to reference miRNA
sequences [23]. The altered seed sequence can cause
substantial differences in the repertoire of predicted
mRNA targets. tDRs are the product of either active
cleavage or an artifact of small RNA library construction.
The parent tRNAs are adaptor molecules with a length
typically ranging from 73 to 94 nucleotides. It is specu-
lated that the cleavage of tRNAs by an RNAse III enzyme,
angiogenin, may occur in a number of reactive conditions
to produce tRNA-derived halves (tRHs) [24, 25]. The
osRNAs we tried to detect include rRNA, snoRNAs,
snRNA, lincRNA, and other miscellaneous sRNAs.
Although sRNA isolation and sRNAseq have primarily
been used to quantify miRNAs, it is not completely
understood as to what extent RNA isolation and sRNA
library kits capture other types of sRNAs. Furthermore,
there are many commercially available sRNA extraction
kits, and the field would greatly benefit from a carefully
designed study to evaluate and compare kit efficiency
and reliability. Motivated by these reasons, we bench-




Five miRNA extraction kits were obtained: Qiagen Circu-
lating Nucleic Acid Kit (NAK), ThermoFisher Scientific
Ambion TRIzol LS Reagent, Qiagen miRNEasy, Qia-
Symphony RNA extraction kit and the Exiqon MiRCURY
RNA Isolation Kit. Highly pure diethyl pyrocarbonate
(DEPC)-free and nuclease-free water were purchased
from Qiagen.
Sample handling
After obtaining informed consent, blood from a single
subject was collected in pre-chilled tubes containing
ethylenediamine-tetra-acetate and placed on ice. Samples
were centrifuged at 3,000 x g for 10 min, aliquoted and
stored at -80 °C until further analyses were performed.
sRNAs from the serum of a single subject were extracted
four times per kit. For each replicate, 200 μl of serum was
used. RNA was extracted with the miRNEasy Serum/
Plasma Kit, QIAamp Circulating NAK, miRCURY RNA
Isolation—BioFluids Kit, and with Ambion TRIzol LS re-
agent according to manufacturer’s instructions. RNA was
extracted on the QIAsymphony SP (Qiagen Corporation,
Germany) using the QIAsymphony RNA Kit (Qiagen,
931636) and protocol RNA_CT_400_V7, which incorpo-
rates DNase treatment. The resulting RNA was eluted
with RNase free water and stored at −80 °C until use.
Samples were initially quantified using a Qubit fluoromet-
ric RNA assay (Life Technologies, Grand Island, NY).
Additional analyses of purity and total RNA quantification
were performed using a NanoDrop spectrophotometer
(Thermo Scientific) and Agilent RNA 6000 Pico chip
(Agilent) according to the manufacturer’s protocol using
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the reagents, chips, and ladder provided in the kit. The
RNA concentration were measured using Qubit. However,
since the targets are extracellular miRNA, the concen-
tration were often below the detection threshold. Add-
itionally, we verified the RNA concentration using
Agilent Bioanalyzer. The concentrations are reported in
Additional file 1: Table S1.
Next-generation small RNA sequencing
RNAseq was performed by the Vanderbilt Technologies
for Advanced Genomics core (VANTAGE). Libraries
were prepared using the TruSeq Small RNA sample
preparation kit (Illumina, San Diego, CA). The sRNA
protocol specifically ligates RNA adapters to mature
miRNAs harboring a 5’-phosphate and 3’-hydroxyl group
as a result of enzymatic cleavage by RNase III processing
enzymes, e.g., Dicer. In the first step, RNA adapters were
ligated onto each end of the sRNA, and reverse tran-
scription was used to create single-stranded cDNA. This
cDNA was then PCR amplified for 18 cycles with a uni-
versal primer and a second primer containing one of 20
uniquely indexed tags to allow multiplexing. Size-selection
of the cDNA constructs was performed using a 3% gel
cassette on the Pippin Prep (Sage Sciences, Beverly, MA)
to include only mature miRNAs and other sRNAs in the
5–40 bp size range and to remove adapter-adapter prod-
ucts. The resulting cDNA libraries then underwent a qual-
ity check on the Agilent Bioanalyzer HS DNA assay
(Agilent, Santa Clara, CA) to confirm the final library size
and on the Agilent Mx3005P quantitative PCR machine
using the KAPA library quantification kit (Illumina, San
Diego, CA) to determine concentration. A 2 nM stock
was created, and samples were pooled by molarity for
equimolar multiplexing. From the pool, 10 pM of the pool
was loaded into each well of the flow cell on the Illumina
cBot for cluster generation. The flow cell was then loaded
and sequenced on the Illumina NextSeq500 to obtain at
least 15 million single end (1x50 bp) reads per sample.
The raw sequencing reads in BCL format were processed
through CASAVA-1.8.2 for FASTQ conversion and de-
multiplexed. The RTA chastity filter was applied, and only
PF (pass filter) reads were retained for further analysis.
Bioinformatics and data analyses
We implemented a custom in-house data analysis pipe-
line [19] for sRNAseq data processing. We categorized
ex-sRNAs into four major categories: miRNAs, isomiRs,
tDRs, and osRNAs. Cutadapt [26] was used to trim 3’
adapters for raw reads. Multi-perspective quality control
[27] on raw data was performed using QC3 [28]. All
reads with lengths less than 16nts in length were dis-
carded. The adaptor-trimmed reads were formatted into
a non-redundant FASTQ file, where the read sequence
and copy number was recorded for each unique tag. The
usable unique reads were mapped to the whole genome
by Bowtie1 [29] allowing only one mismatch. In
addition, our pipeline takes into consideration non-
templated nucleotide additions [30–33] at the 3’ end of
miRNAs during alignment, resulting in a more accurate
miRNA expression quantification. The miRNA coordi-
nates were extracted from miRBase. The tRNA (tDR)
coordinates were prepared by combining the latest
UCSC tRNA database GtRNAdb [34] with the tRNA loci
of mitochondria from the Ensembl database [35]. The
osRNA coordinates were extracted from the Ensembl
database. The tDR reads were used not only for tDR
quantification, but also for tRNA mapping position
coverage analysis. ex-sRNAs were divided into three
major categories: miRNAs, tDRs, and osRNAs (including
sRNAs-derived from parent long non-coding RNAs
(lncRNAs), snoRNAs, snRNAs, and miscellaneous RNAs
in the Ensembl database). IsomiRs were detected by
matching alignment of the reads at +1 or +2 positions
from the start of the 5’ annotation of miRNAs.
The map and cluster analysis were performed using
Heatmap3 [36] to evaluate the relationship between
repeated samples based on the sRNA reads aligned.
Furthermore, we computed intra-class correlation (ICC),
a statistical measure of the homogeneity between more
than two groups [37]. ICC (R package “irr”) was used to
assess each kit’s agreement for sRNA expression measured
from the replicates. ICC is a numerical value ranging from
0 to 1, where a higher value indicates more agreement
among repeats. Additionally, we used Levene’s test [38] (R
lawstat package) to assess the quality of variances for the
sRNAs detected among repeats. Each kit was also evalu-
ated based on the number of sRNA detected.
Results
The yields of small RNA were measured by Agilent
Bioanalyzer and varied greatly (by at least one order of
magnitude) (Table S1). We computed the coefficients of
variance (CV) of yields within each kit as assessments of
the repeatability of yields. MiRCURY kit achieved the
lowest CV of 0.04, followed by Ambio TRIzol (CV = 0.29),
QiaSymphony (CV = 0.31), Circulating NAK (CV = 1.05)
and miRNAEasy had the highest CV of 1.31.
The performance of each kit was first evaluated for
sequencing quality and aligned reads. The factors we
considered included: total number of reads sequenced,
number of reads aligned to each of the sRNA classes,
variation in number of reads, multiple alignment issues
(reads perfectly mapped to multiple) genomic locations,
and unmapped reads (Fig. 1, Additional file 1: Table S2).
In regards to the total number of reads sequenced, Cir-
culating NAK produced the most reads with an average
of 32.9 million over the four replicates. However, the
majority of the reads (83%) in samples isolated by the
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Fig. 1 Pie chart that depicts the percentage of number of reads in different alignment categories: miRNA (include isomiR), tDR, osRNA, other
mapped reads, unmapped. For any sRNA sequencing project on tissue, the unmapped rate will be at least 50%. The unmapped rate will be
even higher for extracellular sRNA sequencing because low sRNA content in serum
Fig. 2 a Cluster and heatmap results for miRNA. b Cluster and heatmap results for isomiRs. c Cluster and heatmap results for detected tRNAs.
d Cluster and heatmap results for miscellaneous sRNAs
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Circulating NAK were not mapped to the human gen-
ome. In contrast, QiaSymphony produced the fewest
number of reads with 6.6 million; yet, 37% were mapped
to the human genome. Ambion TRIzol yielded 11 mil-
lion reads with 54% mapping, which was the highest of
any method tested. All kits had at least 50% of reads not
mapped to human genome which suggested that these
reads were not RNA reads. For reads mapped to sRNAs,
Ambion TRIzol consistently produced the most reads
for miRNAs (23.1%), tDRs (7.2%), and osRNAs (23.1%).
Circulating NAK performed poorly for all sRNAs
species. Because equal amounts of the sequencing library
from each replicate were pooled onto the same lane of
Illumina NextSeq500, ideally, the number of reads se-
quenced for each sample should be roughly equal. How-
ever, variability in sequencing depth can be caused by
Fig. 3 Intra-class correlation coefficient ranges from 0 to 1. Higher number indicates more agreement among replicates
Fig. 4 a Number of detected miRNA. b Number of detected isomiR. c Number of detected tRNA. d Number of detected miscellaneous RNA.
X-axis denotes the read count threshold used for detection. As the detection threshold increased, less RNAs were identified
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many factors, including sample quality and statistical
variation [39]. Since we used 20 technical replicates of
the same sample, the observed variation likely reflects
the efficiency and native difference of the kits rather
than the sample quality. The completed read count table
for the four types of sRNA are provided as supplemen-
tary data (Additional file 1: Table S3-S6).
We conducted unbiased cluster analysis using Heatmap3
[40] for each of the four major sRNA categories (Fig. 2).
The cluster analysis essentially measures the repeatability
of each kit, and inherent differences among the kits will
cause some variability in the sRNA data. In contrast, repli-
cate analyses of the same kit are expected to perform simi-
larly and tightly cluster. For miRNAs, replicates using
Ambion TRIzol, QiaSymphony and Circulating NAK clus-
tered together; for isomiRs, replicates using Circulating
NAK clustered together; for tDRs, replicates using Ambion
TRIzol and Circulating NAK clustered together; for
osRNA, Ambion TRIzol, miRCURY, and QiaSymphony
clustered together. Overall, Ambion TRIzol and Circulat-
ing NAK produced the best cluster results for replicates.
We used ICC within each kit (based on four repeats
per kit) to measure the repeatability of the extraction
kits. For miRNAs, QiaSymphony achieved the highest
ICC of 0.74; for isomiRs, tDRs, and osRNA, Circulating
NAK achieved the highest ICCs of 0.79, 0.97 and 0.96,
respectively. We also computed the ICC across all 20
samples to capture the overall homogeneity. It is worth
noting that miRNAs had the worst overall ICC of 0.28,
followed by isomiRs and osRNA. The mean ICC for tDRs
across all isolated methods was 0.9 (Fig. 3, Additional
file 1: Table S7). Using Levene’s test we found no sig-
nificant difference in the equality of variances for the
sRNAs detected among repeats (p = 1).
Next, we examined the number of detected sRNAs by
each kit (Fig. 4). To determine if a sRNA was detected,
we selected several detection thresholds which have
been commonly used for assessing sRNA detection (read
counts >1, >5, >10, >15, >20) [41]. Circulating NAK con-
sistently detected the greatest number of miRNAs and iso-
miRs at all detection thresholds. For tDRs, the miRNEasy
kit detected the most sRNAs at all thresholds, but Circu-
lating NAK also performed equally well for the lowest and
highest detection thresholds. For osRNAs, the miRCURY
kit performed the best at all detection thresholds. We also
performed the tRNA alignment pattern analysis (5’ end on
the left, 3’ end on the right), color coded by anticodon
type, which showed some difference in alignment patterns
of tDRs among the kits (Fig. 5). For Ambion TRIzol and
miRNEasy, a higher percentage of the reads were aligned
to parent tRNAs, and Circulating NAK and QiaSymphony
had the lowest percentage of reads aligned to parent
tRNAs. The read distributions by anticodon type of tRNA
were also different among the kits.
However, the kit that detects the most sRNAs might
also detect the most singleton miRNAs. We define a
singleton as a species that is detected by one of the five
isolation kits. Circulating NAK detected the most single-
ton miRNAs, which explains why Circulating NAK also
detected the most miRNAs. Very few singleton isomiRs
and no singleton tDRs were detected. miRCURY de-
tected the most singleton osRNAs (Fig. 6). A list of the
top singleton miRNAs, computed and ranked by the
differences between one kit and the other four kits, is
available in the Additional file 1: Table S8. Using Levene’s
test, we found that the commonly detected sRNAs have
no significant amount of difference in level of expression
among kits. The presence of singleton sRNA may rep-
resent each kit’s uniqueness and can be interpreted as
either advantageous or biased. A list of the top other
Fig. 5 tRNA positional alignment distribution. Color indicates the
tRNA by anticodon type. The x-axis denotes the position of tRNA
from 0 to the end of tRNA. The y-axis denotes the cumulative read
fractions. Visible quantity difference can be seen in the tRNA type
detected by different kits. This suggests that there are selection bias
of tRNA in by the kits
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sRNAs, computed and ranked by the differences be-
tween one kit and the other four kits, is available in the
Additional file 1: Table S9.
Discussion
ex-sRNAs have the potential to make a strong impact
in the field of biomarker research. The ability to detect
ex-sRNA from easily obtainable medium, such as
serum or liquid biopsies, can greatly enhance the cap-
ability of molecular diagnose [42–44]. A reproducible
biomarker also provides valuable insights into specific
biological traits at the molecular and cellular level.
While having great potential, the analysis of ex-sRNAs
from high throughput sequencing pose serious bio-
informatics challenges [45]. Currently, one of the diffi-
culties preventing the full fruition of ex-sRNA as a
reliable biomarker analysis is the consistency of detec-
tion. Another potential issue clouding the future of ex-
sRNAs is the obscurity of the origin of these nucleic
acids in human serum/plasma. Some arguments have
been made that ex-miRNAs can be released into the
blood stream directly from blood cells [46] and/or
other tissue cells [47].
Our study was not designed to study the origin of
sRNAs detected in serum. Instead, our study was
motivated by the lack of consensus over the best ap-
proach for ex-sRNA isolation. To tackle this problem,
we designed a thorough experiment to evaluate the per-
formance of five sRNA isolation kits that have been
previously used for isolating ex-miRNAs. Through care-
ful examination of the sequencing data, we can safely
conclude that not only were ex-miRNAs detectable in
serum, but other species of sRNA, including, ex- iso-
miRs, ex-tDRs, and ex-osRNAs, were also detectable.
We primarily examined the performance of the isolation
kits from three aspects: 1) the number of reads
sequenced and aligned to each species of sRNA; 2) the
repeatability of the replicates within each kit; 3) the
number of sRNAs detected. While each kit was used per
manufacturer’s instructions, and the amount of nucleic
acid input into each replicate for each kit was the same,
there were notable kit-specific differences in RNA yield.
Each kit designated a different volume of water for elu-
tion which is reflected in the concentration and total
amount of RNA yielded, and may impart a certain level
of bias in our results.
Fig. 6 Venn diagrams to represent the intersection and uniquely detected sRNAs, detection threshold used was read count > 10. a The
intersection of detected miRNA by all kits. b The intersection of detected isomiRs by all kits. c The intersection of detected tRNA by all kits.
d The intersection of detected miscellaneous sRNA by all kits
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All five kits had poor mapping rate to human genome
(<50%), suggesting all kits captured a large amount of
miscellaneous material. The phenomenon of high
unmapped rates is quite common for high throughput
sequencing experiments, however the scale of the
unmapped rate depends on the sample quality, type of
sequencing, and the abundance of the source RNA. In
exome sequencing, it had been shown that the un-
mapped rate is anywhere from 5 to 19% [48]. For small
RNA sequencing on tissue samples, we have previously
reported the unmapped rate between 30 and 40% [20].
Our current study focused on ex-sRNAs from serum
which is of much less abundance compared to tissue
samples. The high unmapped rate is a reflection of the
nature of the experiment.
Ambion TRIzol had the most reads annotated as
sRNAs; however, the observed increase in genomic
alignments did not translate into a higher number of
detected sRNAs, suggesting either there was selection
bias for Ambion TRIzol or the reads were dominated
by miRNAs with high expression. Reproducibility was
evaluated using cluster analysis and ICC, and Circulat-
ing NAK had the highest repeatability overall. In terms
of the number of ex-sRNAs detected, Circulating NAK
detected the most ex-osRNAs, ex-isomiRs and also
performed well for ex-tDRs. miRCURY detected the
highest number of ex-osRNAs. However, currently, ex-
osRNAs are the least studied sRNAs and their bio-
logical functions remain largely unknown.
In sRNA sequencing, especially extracellular sequen-
cing, the detection threshold of miRNA can significantly
affect the number of sRNAs detected. In our study, for
demonstration purposes, we have used detection thresh-
old of read counts >1, >5, >10, >15, >20. In reality,
sRNA detected with less than 10 read counts are difficult
to replicate by RT-PCR. For reliable sRNA detection, it
is recommended to set a detection threshold with read
count > 10 [49].
Conclusions
In conclusion, our data suggest that each isolation kit
displays inherent performance characteristics that may
be construed as biased, or advantageous, depending
upon the downstream application and number of sam-
ples that require processing. The Circulating NAK con-
sistently generated the fewest number of reads mapped
to the genome, in comparison to the best performing
method, Ambion TRIzol, where 10% of the detected
miRNAs, 7.2% of the tDRs and 23.1% of osRNAs were
mapped. The performance of the other methods was
intermediary, with QiaSymphony mapping 14% of osR-
NAs and miRNEasy mapping 4.6% of tDRs and 2.9% of
miRNAs, making it the second best performing kit in
terms of sRNA extraction efficiency. However, the
Circulating NAK kit detected the highest number of
miRNAs. These data suggest that the choice of sRNA
isolation kits for ex-sRNA analysis is not trivial and may
introduce significant bias that must be addressed when
interpreting outcomes.
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